A privately held New York biotech, formerly Kallyope, that rebranded in October 2026 to focus on migraine, raised $94 million and is running Phase III trials of elismetrep, an oral TRPM8 blocker for acute migraine.
A privately held New York biotech, formerly Kallyope, that rebranded in October 2026 to focus on migraine, raised $94 million and is running Phase III trials of elismetrep, an oral TRPM8 blocker for acute migraine.
